{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurofibroma+Plexiform", "query": { "condition": "Neurofibroma Plexiform" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 57, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurofibroma+Plexiform&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T23:22:43.795Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02407405", "title": "MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neurofibromatosis 1 (NF1)", "Plexiform Neurofibromas (PN)" ], "interventions": [ { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2016-01-07", "completion_date": "2030-01-01", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-05-21T23:22:43.795Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02407405" }, { "nct_id": "NCT04954001", "title": "Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neurofibromatosis 1", "Plexiform Neurofibroma", "NF1" ], "interventions": [ { "name": "FCN-159", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "2 Years to 70 Years" }, "enrollment_count": 160, "start_date": "2021-03-26", "completion_date": "2025-03-30", "has_results": false, "last_update_posted_date": "2024-11-12", "last_synced_at": "2026-05-21T23:22:43.795Z", "location_count": 5, "location_summary": "Los Angeles, California • Gainesville, Florida • St. Petersburg, Florida + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04954001" }, { "nct_id": "NCT02101736", "title": "Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NF1", "Neurofibromatosis", "Plexiform Neurofibromas" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 45, "start_date": "2014-06", "completion_date": "2022-02-16", "has_results": true, "last_update_posted_date": "2023-05-24", "last_synced_at": "2026-05-21T23:22:43.795Z", "location_count": 12, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02101736" }, { "nct_id": "NCT02124772", "title": "Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Trametinib", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Month to 17 Years" }, "enrollment_count": 139, "start_date": "2015-01-15", "completion_date": "2020-12-29", "has_results": true, "last_update_posted_date": "2021-07-14", "last_synced_at": "2026-05-21T23:22:43.795Z", "location_count": 10, "location_summary": "Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02124772" }, { "nct_id": "NCT06961565", "title": "PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NF1 Mutation", "Neurofibroma Plexiform", "Neurofibroma, Plexiform", "Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)", "Neurofibromatosis Type 1 (NF1)" ], "interventions": [ { "name": "PAS-004 Tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pasithea Therapeutics Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2025-05-30", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-05-21T23:22:43.795Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06961565" }, { "nct_id": "NCT01275586", "title": "Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Neurofibromatosis", "NF1", "Neurofibromas" ], "interventions": [ { "name": "Tasigna", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2011-01", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2017-04-12", "last_synced_at": "2026-05-21T23:22:43.795Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01275586" }, { "nct_id": "NCT05238909", "title": "Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neurofibromatosis 1", "NF1", "Neurofibromatosis Type 1" ], "interventions": [], "intervention_types": [], "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 200, "start_date": "2022-03-04", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-05-21T23:22:43.795Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05238909" }, { "nct_id": "NCT00716469", "title": "Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neurofibroma" ], "interventions": [ { "name": "LS11", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 7, "start_date": "2008-07", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2015-04-15", "last_synced_at": "2026-05-21T23:22:43.795Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00716469" }, { "nct_id": "NCT03820778", "title": "Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Neurofibromatosis 1", "Neurofibroma", "Atypical Neurofibroma", "Atypical Neurofibromatosis", "Plexiform Neurofibroma", "Von Recklinghausen Disease" ], "interventions": [ { "name": "Whole Body MRI", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Children's National Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "8 Years to 30 Years" }, "enrollment_count": 10, "start_date": "2018-07-12", "completion_date": "2022-08-01", "has_results": false, "last_update_posted_date": "2021-03-02", "last_synced_at": "2026-05-21T23:22:43.795Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03820778" }, { "nct_id": "NCT02180867", "title": "Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alveolar Soft Part Sarcoma", "Angiomatoid Fibrous Histiocytoma", "Atypical Fibroxanthoma", "Clear Cell Sarcoma of Soft Tissue", "Epithelioid Malignant Peripheral Nerve Sheath Tumor", "Epithelioid Sarcoma", "Extraskeletal Myxoid Chondrosarcoma", "Extraskeletal Osteosarcoma", "Fibrohistiocytic Neoplasm", "Fibrosarcoma", "Inflammatory Myofibroblastic Tumor", "Intimal Sarcoma", "Leiomyosarcoma", "Liposarcoma", "Liver Embryonal Sarcoma", "Low Grade Fibromyxoid Sarcoma", "Low Grade Myofibroblastic Sarcoma", "Malignant Peripheral Nerve Sheath Tumor", "Malignant Skin Granular Cell Tumor", "Malignant Triton Tumor", "Mesenchymal Chondrosarcoma", "Myxofibrosarcoma", "Myxoid Chondrosarcoma", "Myxoinflammatory Fibroblastic Sarcoma", "Nerve Sheath Neoplasm", "PEComa", "Pericytic Neoplasm", "Plexiform Fibrohistiocytic Tumor", "Sclerosing Epithelioid Fibrosarcoma", "Skin Glomus Tumor", "Stage IB Soft Tissue Sarcoma AJCC v7", "Stage IIB Soft Tissue Sarcoma AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Synovial Sarcoma", "Undifferentiated High Grade Pleomorphic Sarcoma of Bone" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 140, "start_date": "2014-07-11", "completion_date": "2026-12-24", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-05-21T23:22:43.795Z", "location_count": 365, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02180867" } ] }